MDM4 and breast cancer: A 4-nitrobenzofuroxan derivative, designated XI-006 (NSC207895) was identified and was shown to repress MDM4 promoter activity resulting in decreased MDM4 mRNA and protein expression and cell viability in MDM4 amplified breast cancer cell lines18.